23 / 27
EORTC QLQ-C30:
deterioration of role function, general pain, and diarrhoea
EORTC QLQ-HCC18:
nutrition and body image
The figures denote the overall risk of observing a meaningful worsening using the HR with confidence bounds.
EORTC = European Organisation for Research and Treatment of Cancer; HR = hazard ratio; HRQoL = health-related quality of life; LCL = lower confidence limit; QoL = quality
of life; QLQ = quality of life questionnaire; UCL = upper confidence limit.
1. Vogel A
et al
. Abstract presented at the 2017 ESMO Annual Congress, Madrid, Spain. Sep 8–12, 2017
.
HR
LCL
UCL
Abdominal swelling
1.00 0.819 1.211
Sex life
0.94 0.767 1.145
Fever
0.90 0.755 1.084
Pain
1.14 0.966 1.347
Nutrition
0.81 0.681 0.952
Body image
0.79 0.675 0.933
Jaundice
0.94 0.786 1.134
Fatigue
0.93 0.800 1.091
HR
LCL
UCL
Physical functioning
0.91 0.769 1.070
Role functioning
0.83 0.705 0.970
Emotional functioning
0.96 0.811 1.132
Cognitive functioning
1.07 0.903 1.258
Social functioning
1.05 0.887 1.238
Fatigue
0.94 0.804 1.091
Nausea and vomiting
1.05 0.869 1.276
Pain
0.82 0.697 0.953
Dyspnoea
0.98 0.811 1.186
Insomnia
1.18 0.980 1.423
Appetite
loss
1.01 0.857 1.193
Constipation
1.08 0.883 1.317
Diarrhoea
0.53 0.449 0.630
Financial difficulties
0.94 0.759 1.159
Global health
status/QoL
1.01 0.870 1.180
Summary score
0.87 0.754 1.013
Time to Clinically Meaningful Worsening of HRQoL Domains
Favours
sorafenib
Favours
lenvatinib
0,5 0,75 1 1,25 1,5
Favours
sorafenib
Favours
lenvatinib
0,5 0,75 1 1,25 1,5
Compared with patients treated with sorafenib, patients treated with lenvatinib observed
delays in: